China Bio-view Q3 2008

CHINA-BIO

China Sky One Medical, Inc. Received Chinese Regulatory Approval for Four New Drugs

In June -- China Sky One Medical, Inc., a China-based life-sciences company for pharmaceutical, medicinal and diagnostic kit products, announced that it obtained approval from the State Food and Drug Administration (SFDA) in the People's Republic of China for four new drugs: Tobramycin Eye Drops, Compound Zinc Sulfate Eye Drops, Ofloxacin Suppositories and Ofloxacin Gels.

Tobramycin Eye Drops have been approved for the treatment of acute infection on eyelids. Compound Zinc Sulfate Eye Drops have been approved for the treatment of acute and chronic conjunctivitis and trachoma. Ofloxacin Suppositories have been approved for the treatment for bactericidal colpitis, and Ofloxacin Gels have been approved for the treatment for bactericidal injection. The Company estimates the size of the each market at approximately $ 2 million USD to $2.4 million USD

The new approvals bring the total number of China Sky One's externally used products to 53 and its total marketed products to 102, giving the Company one of the most comprehensive pharmaceutical product portfolios in China.

Improved Milk Production in Cows From Cactus Cattle Feed
In June, China Kangtai Cactus Biotech Inc.,a vertically integrated grower, developer, manufacturer and marketer of a variety of cactus-based consumer products in China, announced today test results from studies conducted of cows that received the Company's Cactus Cattle Feed. The studies, which included 30 cows, were conducted in conjunction with the Company's application for a Certificate of National Invention Patent and showed cows that received the Company's Cactus Cattle Feed increased milk production by approximately 15.2% during the twenty-day trial period.

The Company also conducted a second test, evaluating the ability of cattle to produce milk under adverse environmental conditions, including cold temperatures and strong wind conditions. The study selected 100 milk cows between the age of 2.5 to 3 years, and divided them into two groups. The cows in the control group were fed with the normal feed which was made by the ranch. The cows in the experimental group received the same feed, but also added 1kg cactus cattle feed to each ton of the normal feed. The milk production of the experimental group increased to 1,372kg from 1,350kg despite the adverse conditions. The milk production of the control group decreased to 1,286kg from 1,380kg. The results suggest that the use of cactus cattle feed additives could increase milk production by 8.44%.


Genesis Pharmaceuticals Closes $30 Million Private Note Placement
In June, Genesis Pharmaceuticals Enterprises, Inc., a leading pharmaceutical company in the People's Republic of China, stated that it successfully completed a private placement of $30,000,000 of its three year convertible notes.

The Notes carry an annual interest rate of 6.0% and are convertible into shares of the Company's Common Stock at a conversion price of $0.20 per share. In connection with the private placement of the Notes, the Company issued to purchasers of the Notes an aggregate of 75,000,000 five-year warrants to purchase shares of its Common Stock at an exercise price of $0.25 per share. The lead investor in the private placement was Pope Investments, LLC.


Ryan Baidya

California Takshila University